Objective: Approximately 50% of cancer patients develop bone metastases in their natural disease history. The management of metastatic bone disease requires a multidisciplinary approach. Both radiofrequency ablation (RFA) and radiation therapy (RT) were safe and effective in the management of painful metastases, even if they rely on totally different action mechanisms. A synergistic combination of RT and RFA seems to result in a better pain control. A systematic review was performed to describe the feasibility and effectiveness of the association between RFA and RT in the treatment of metastatic bone pain in oligo-metastatic patients, evaluating its role in alleviating bone pain, reducing the risk of fractures, and consequently ensuring a better quality of life.
Materials And Methods: A systematic database search was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This systematic review included studies that reported populations meeting the following inclusion criteria: (I) confirmed bone metastases in adult patients; (II) active bone metastases pain; (III) patients treated with combined RFA-RT; (IV) Original studies.
Results: Three papers that evaluated the combined treatment with doses ranging from moderately hypofractionated three-dimensional conformal RT (3D-CRT) and stereotactic body radiation therapy (SBRT) schedules were selected.
Conclusions: The RFA-RT combined strategy appears to be promising in terms of efficiency and safety with adequate pain control and quality of life improvement. Positive effects on time to local failure and overall survival increase were also observed. Further prospective studies are needed to better delineate RFA-RT treatment benefits.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.26355/eurrev_202105_25930 | DOI Listing |
Purpose: We hypothesised that applying radiomics to [F]PSMA-1007 PET/CT images could help distinguish Unspecific Bone Uptakes (UBUs) from bone metastases in prostate cancer (PCa) patients. We compared the performance of radiomic features to human visual interpretation.
Materials And Methods: We retrospectively analysed 102 hormone-sensitive PCa patients who underwent [F]PSMA-1007 PET/CT and exhibited at least one focal bone uptake with known clinical follow-up (reference standard).
J Orthop
August 2025
Department of Orthopaedic Surgery, Hospital Clínico San Carlos, Spanish National Reference Center for Musculoskeletal Oncological Surgery, Calle Del Prof Martín Lagos, S/N, Moncloa, 28040, Madrid, Spain.
Objectives: To describe the functional outcomes, complications, and reconstruction types in patients with periacetabular metastases and to propose an extension of the Harrington classification.
Methods: Twenty-eight patients (13 males, 15 females) with a mean age of 63.8 ± 15.
Int Urol Nephrol
January 2025
Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany.
Purpose: To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Methods: Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression.
BJC Rep
January 2025
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background: Osteosarcoma is the most common malignant bone tumour with limited treatment options and poor outcomes in advanced metastatic cases. Current immunotherapies show limited efficacy, highlighting the need for novel therapeutic approaches. Systemic immune activation by Toll-like receptor 4 (TLR4) immunostimulants has shown great promise; however, current TLR4 agonists' toxicity hinders this systemic approach in patients with osteosarcoma.
View Article and Find Full Text PDFPhys Med Biol
January 2025
Charles Sturt University, Albury-Wodonga, NSW, Albury, New South Wales, 2640, AUSTRALIA.
Bone is a common site for the metastasis of malignant tumors, and Single Photon Emission Computed Tomography (SPECT) is widely used to detect these metastases. Accurate delineation of metastatic bone lesions in SPECT images is essential for developing treatment plans. However, current clinical practices rely on manual delineation by physicians, which is prone to variability and subjective interpretation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!